Published in Cancer Res on September 01, 2008
Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov (2012) 5.26
Autophagy genes in immunity. Nat Immunol (2009) 3.76
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity (2014) 2.86
Can autophagy promote longevity? Nat Cell Biol (2010) 2.55
Cross-priming in health and disease. Nat Rev Immunol (2010) 2.51
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
The multiple roles of autophagy in cancer. Carcinogenesis (2011) 1.63
Autophagy and its role in MHC-mediated antigen presentation. J Immunol (2009) 1.54
Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol (2011) 1.51
Autophagy and cancer cell metabolism. Semin Cell Dev Biol (2012) 1.32
Autophagy and cancer. Cold Spring Harb Perspect Biol (2012) 1.30
Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res (2011) 1.30
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol (2014) 1.29
Autophagy and adaptive immunity. Immunology (2010) 1.26
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res (2011) 1.24
Antigen processing via autophagy--not only for MHC class II presentation anymore? Curr Opin Immunol (2010) 1.21
Autophagy in the regulation of pathogen replication and adaptive immunity. Trends Immunol (2012) 1.21
Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal (2011) 1.18
Autophagy in the immune system. Immunology (2014) 1.12
Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy (2014) 1.10
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc Natl Acad Sci U S A (2015) 1.10
Autophagy in tumor suppression and cancer therapy. Crit Rev Eukaryot Gene Expr (2011) 1.08
When autophagy meets viruses: a double-edged sword with functions in defense and offense. Semin Immunopathol (2010) 1.07
CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease. J Clin Invest (2012) 1.07
Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One (2014) 1.02
The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Res (2012) 1.01
Autophagy in the immune response to tuberculosis: clinical perspectives. Clin Exp Immunol (2011) 1.00
Presentation of phagocytosed antigens by MHC class I and II. Traffic (2012) 0.98
Modulation of inflammation by autophagy: Consequences for human disease. Autophagy (2015) 0.98
Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. J Clin Invest (2014) 0.95
Autophagy, nutrition and immunology. Mol Aspects Med (2011) 0.94
Dying cells actively regulate adaptive immune responses. Nat Rev Immunol (2017) 0.94
Autophagy in inflammatory diseases. Int J Cell Biol (2011) 0.94
Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology (2012) 0.94
Pharmacological regulators of autophagy and their link with modulators of lupus disease. Br J Pharmacol (2014) 0.93
Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest (2013) 0.92
Autophagy and mechanisms of effective immunity. Front Immunol (2012) 0.90
The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome. Mol Cell Proteomics (2013) 0.89
Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett (2012) 0.89
Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Nat Rev Clin Oncol (2016) 0.88
Autophagy-associated immune responses and cancer immunotherapy. Oncotarget (2016) 0.88
Of LAP, CUPS, and DRibbles - Unconventional Use of Autophagy Proteins for MHC Restricted Antigen Presentation. Front Immunol (2015) 0.86
MHC presentation via autophagy and how viruses escape from it. Semin Immunopathol (2010) 0.86
Immunological significance of the accumulation of autophagy components in oral squamous cell carcinoma. Cancer Sci (2014) 0.84
Autophagy and selective deployment of Atg proteins in antiviral defense. Int Immunol (2012) 0.84
Immunopathogenesis Versus Protection in Dengue Virus Infections. Curr Trop Med Rep (2014) 0.83
Multiple vaccinations: friend or foe. Cancer J (2011) 0.83
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. Oncoimmunology (2015) 0.83
Nanomaterials and autophagy: new insights in cancer treatment. Cancers (Basel) (2013) 0.83
The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses. Immunol Lett (2009) 0.82
Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities. Front Immunol (2012) 0.82
Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? Vaccine (2015) 0.82
Autophagy in thyroid cancer: present knowledge and future perspectives. Front Endocrinol (Lausanne) (2015) 0.82
Autophagy and immunity - insights from human herpesviruses. Front Immunol (2012) 0.82
Immunotherapy of brain cancers: the past, the present, and future directions. Clin Dev Immunol (2011) 0.81
Intersection of autophagy with pathways of antigen presentation. Protein Cell (2012) 0.81
Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity. Mol Cell Proteomics (2016) 0.80
Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles). J Immunother (2014) 0.80
Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression. Sci Rep (2016) 0.79
Antigen processing by macroautophagy for MHC presentation. Front Immunol (2011) 0.79
Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) (2013) 0.78
Tumor-derived autophagosomes (DRibbles) induce B cell activation in a TLR2-MyD88 dependent manner. PLoS One (2013) 0.78
Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. Biomed Res Int (2015) 0.78
Regulation of SIV antigen-specific CD4+ T cellular immunity via autophagosome-mediated MHC II molecule-targeting antigen presentation in mice. PLoS One (2014) 0.78
Interactions between Autophagy and Inhibitory Cytokines. Int J Biol Sci (2016) 0.78
Enhanced Therapeutic Efficacy in Cancer Patients by Short-term Fasting: The Autophagy Connection. Front Oncol (2016) 0.77
Autophagy, viruses, and intestinal immunity. Curr Opin Gastroenterol (2014) 0.77
Autophagy in toxicology: self-consumption in times of stress and plenty. J Appl Toxicol (2012) 0.77
Crosstalk between autophagy and apoptosis in RAW 264.7 macrophages infected with ectromelia orthopoxvirus. Viral Immunol (2013) 0.77
Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine. J Exp Clin Cancer Res (2015) 0.76
P2X7 receptor activation impairs exogenous MHC class I oligopeptides presentation in antigen presenting cells. PLoS One (2013) 0.76
Antigen processing for MHC presentation by autophagy. F1000 Biol Rep (2010) 0.76
Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet. Front Oncol (2016) 0.76
Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity. Front Immunol (2016) 0.76
Rapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based Vaccine. PLoS One (2015) 0.76
An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation. J Transl Med (2014) 0.76
Cross-presentation of antigens by dendritic cells: role of autophagy. Oncotarget (2015) 0.76
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies. Oncotarget (2016) 0.75
Developing an in vitro model of T cell type of large granular lymphocyte leukemia. Leuk Res (2013) 0.75
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine. J Immunother Cancer (2016) 0.75
Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-κB signal pathway. Oncoimmunology (2016) 0.75
The Autophagic Machinery in Viral Exocytosis. Front Microbiol (2017) 0.75
Sorafenib and a novel immune therapy in lung metastasis from hepatocellular carcinoma following hepatectomy: A case report. Mol Clin Oncol (2016) 0.75
Dendritic cells: microbial clearance via autophagy and potential immunobiological consequences for periodontal disease. Periodontol 2000 (2015) 0.75
Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination. PLoS One (2015) 0.75
Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer. Int J Nanomedicine (2015) 0.75
Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. Oncoimmunology (2017) 0.75
Immune responses of dendritic cells combined with tumor-derived autophagosome vaccine on hepatocellular carcinoma. Chin J Cancer Res (2015) 0.75
Autophagy Proteins in Phagocyte Endocytosis and Exocytosis. Front Immunol (2017) 0.75
Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature (2006) 24.39
Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature (2006) 21.40
Autophagy as a regulated pathway of cellular degradation. Science (2000) 17.27
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe (2007) 7.34
Atg8, a ubiquitin-like protein required for autophagosome formation, mediates membrane tethering and hemifusion. Cell (2007) 7.11
Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity (2006) 6.17
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol (2001) 5.15
Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol (2000) 5.14
Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science (2004) 5.10
Innate and adaptive immunity through autophagy. Immunity (2007) 4.11
Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol (2005) 2.65
CD8+ T cell cross-priming via transfer of proteasome substrates. Science (2004) 2.51
Purification and characterization of autophagosomes from rat hepatocytes. Biochem J (1998) 2.20
Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A (2004) 1.51
Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells. J Immunol (2003) 1.08
Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum Gene Ther (2000) 1.08
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol (2010) 4.37
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67
Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity (2004) 3.10
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Dramatic amplification of a rice transposable element during recent domestication. Proc Natl Acad Sci U S A (2006) 2.07
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis (2010) 1.90
Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res (2002) 1.89
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol (2008) 1.69
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol (2011) 1.51
Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol (2003) 1.50
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Crystal structure of dimeric cardiac L-type calcium channel regulatory domains bridged by Ca2+* calmodulins. Proc Natl Acad Sci U S A (2009) 1.41
[1,2-Bis(2-pyridyl-meth-oxy)benzene-κN,O,O',N']bis-(nitrato-κO)copper(II). Acta Crystallogr Sect E Struct Rep Online (2010) 1.41
Science gone translational: the OX40 agonist story. Immunol Rev (2011) 1.39
Are all hypotheses generated before data analysis prospective? J Clin Oncol (2002) 1.38
Draft genome sequence of the mulberry tree Morus notabilis. Nat Commun (2013) 1.38
Synthesis and application of chiral spiro phospholane ligand in Pd-catalyzed asymmetric allylation of aldehydes with allylic alcohols. Org Lett (2005) 1.37
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res (2011) 1.30
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res (2011) 1.24
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther (2003) 1.17
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol (2003) 1.17
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res (2008) 1.12
Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy (2009) 1.10
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother (2010) 1.10
Asymmetric reductive coupling of dienes and aldehydes catalyzed by nickel complexes of spiro phosphoramidites: highly enantioselective synthesis of chiral bishomoallylic alcohols. J Am Chem Soc (2007) 1.08
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res (2004) 1.08
Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer (2009) 1.04
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol (2007) 1.03
Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A (2006) 1.03
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med (2006) 1.02
Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res (2008) 1.02
The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Res (2012) 1.01
Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother (2006) 1.01
Highly enantioselective insertion of carbenoids into O-H bonds of phenols: an efficient approach to chiral alpha-aryloxycarboxylic esters. J Am Chem Soc (2007) 1.00
TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol (2003) 1.00
Reduction of retrovirus-induced immunosuppression by in vivo modulation of T cells during acute infection. J Virol (2004) 0.99
Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis (2011) 0.99
Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. J Immunol (2012) 0.97
Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg (2005) 0.96
Bioinformatics and genomic analysis of transposable elements in eukaryotic genomes. Chromosome Res (2011) 0.96
Miniature inverted-repeat transposable elements: discovery, distribution, and activity. Genome (2013) 0.96
Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology (2012) 0.94
Alteration in abundance and compartmentalization of inflammation-related miRNAs in plasma after intracerebral hemorrhage. Stroke (2013) 0.93
Determinants in CaV1 channels that regulate the Ca2+ sensitivity of bound calmodulin. J Biol Chem (2009) 0.92
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med (2009) 0.91
Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J Immunother (2007) 0.91
CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. J Immunol (2002) 0.91
A comparison of the effectiveness of mitomycin C and 5-fluorouracil in the prevention of peridural adhesion after laminectomy. J Neurosurg Spine (2007) 0.91
Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother (2006) 0.91
HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex. J Biol Chem (2013) 0.91
Enantioselective hydrogenation of α-substituted acrylic acids catalyzed by iridium complexes with chiral spiro aminophosphine ligands. Angew Chem Int Ed Engl (2012) 0.91
Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity. Fitoterapia (2012) 0.90
Strategies for diagnosis of xanthogranulomatous cholecystitis masquerading as gallbladder cancer. Chin Med J (Engl) (2012) 0.89
Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother (2003) 0.89
Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells. J Immunol (2003) 0.89
Enantioselective rhodium-catalyzed addition of arylboronic acids to alpha-ketoesters. Angew Chem Int Ed Engl (2008) 0.88
Associations of cigarette smoking and alcohol consumption with metabolic syndrome in a male Chinese population: a cross-sectional study. J Epidemiol (2014) 0.87
Oxytocin in the periaqueductal gray participates in pain modulation in the rat by influencing endogenous opiate peptides. Peptides (2011) 0.87
Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother (2002) 0.86
Monodentate chiral spiro phosphoramidites: efficient ligands for rhodium-catalyzed enantioselective hydrogenation of enamides. Angew Chem Int Ed Engl (2002) 0.85
Redirecting T cells. N Engl J Med (2011) 0.85
Functional impairment of central memory CD4 T cells is a potential early prognostic marker for changing viral load in SHIV-infected rhesus macaques. PLoS One (2011) 0.85